GE HealthCare Technologies Inc. (GEHC) Stock

GE HealthCare Technologies Inc. trades at a P/E ratio of 15.63, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 18.28 is higher than the current P/E, indicating analysts expect earnings to decline over the next year. The PEG ratio of 2.49 indicates a premium valuation even accounting for growth.

With a beta of 1.29, GE HealthCare Technologies Inc. is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 3.71 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

GE HealthCare Technologies Inc. achieves a profit margin of 11.00%, meaning it retains $11.00 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 14.80% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 26.40% and ROA at 5.87%, the company generates strong returns on invested capital.

GE HealthCare Technologies Inc.'s revenue grew by 2.70% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 51.90% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS industry averages for proper context.

GE HealthCare Technologies Inc. offers a dividend yield of 0.19%, paying $0.13 per share annually. This modest yield below 2% suggests the company prioritizes growth investments over current income. While the dividend provides some return, investors are likely attracted more by capital appreciation potential than income generation. To receive the next dividend, shares must be purchased before the ex-dividend date of 4/25/2025.

The dividend sustainability can be assessed through the payout ratio - GE HealthCare Technologies Inc. pays $0.13 per share in dividends against earnings of $4.76 per share, resulting in a payout ratio of 2.73%. This conservative payout below 30% indicates excellent dividend safety with substantial room for future increases. The company retains most earnings for growth while still rewarding shareholders. The next dividend payment is scheduled for 5/15/2025.

GE HealthCare Technologies Inc. has a market capitalization of $34.06B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 457.88M shares outstanding, the company's ownership is relatively concentrated. As a participant in the X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS industry, it competes with other firms in this sector.

GE HealthCare Technologies Inc.'s book value per share is $20.07, while the current stock price is $77.61, resulting in a price-to-book (P/B) ratio of 3.87. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

21 analysts cover GEHC with 76% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $87.35 implies 12.5% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:4 Strong Buy, 12 Buy, 5 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.